MAAT INDEX

CLAIM #48551 · Pfizer Inc (PFE) · 2025Q1 earnings call · Apr 29, 2025 · due Dec 31, 2025

Additionally, our cost improvement programs are set to deliver operating margin expansion.

David Denton · CFO

PENDING
graded after results covering Dec 31, 2025 are reported

In context

icies. We expect total company full-year 2025 revenues to be in the range of $61 to $64 billion, and full-year 2025 adjusted diluted earnings per share to be in the range of $2.80 to $3.00 a share, which reflects our expectation of strong contributions across our product portfolio and our focused discipline on cost management. As we finish Q1 with earnings strength, and excluding the potential impact related to future trade changes, we are currently trending towards the upper end of our adjusted diluted earnings per share guidance range. In closing, let me emphasize several key aspects of our business. We will continue our focus on executing to maximize the commercial value of our product portfolio. We remain committed to driving value-creating innovation while strengthening our pipeline. Additionally, our cost improvement programs are set to deliver operating margin expansion. Expected productivity gains will be driven by leveraging our digital capabilities and simplifying our business processes. Our improved balance sheet sets the stage for more balanced and enhanced capital deployment, focused on creating value for our shareholders. And with that, I will now turn it back over to Albert for Q&A. Thank you, Dave. Operator, please assemble the Q and let's start the Q&A. Operator: We'll go first to Vamil Divan with Guggenheim. Please go ahead. Vamil Divan: Great. Thanks so much for taking the questions. Maybe two if I could. So one, just appreciate your prepared remarks. We come mentioned the dividend, your commitment to maintaining and growing the dividend over time. But I think we've just gotten started increasing questions about this from investors over the la

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2025Q1 earnings call.